Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,904 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.
Anink J, Van Suijlekom-Smit LW, Otten MH, Prince FH, van Rossum MA, Dolman KM, Hoppenreijs EP, ten Cate R, Ursu S, Wedderburn LR, Horneff G, Frosch M, Vogl T, Gohar F, Foell D, Roth J, Holzinger D. Anink J, et al. Among authors: roth j. Arthritis Res Ther. 2015 Aug 7;17(1):200. doi: 10.1186/s13075-015-0723-1. Arthritis Res Ther. 2015. PMID: 26249667 Free PMC article.
MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever.
Park C, Miranda-Garcia M, Berendes R, Horneff G, Kuemmerle-Deschner J, Ganser G, Huppertz HI, Minden K, Haas JP, Jansson AF, Borte M, Schuetz C, Oommen P, Frosch M, Schlueter B, Richter-Unruh A, Kessel C, Hinze C, Wittkowski H, Roth J, Foell D, Holzinger D. Park C, et al. Among authors: roth j. Rheumatology (Oxford). 2022 Jul 6;61(7):3082-3092. doi: 10.1093/rheumatology/keab729. Rheumatology (Oxford). 2022. PMID: 34559193
Use of MRP8/14 in clinical practice as a predictor of outcome after methotrexate withdrawal in patients with juvenile idiopathic arthritis.
Sumner EJ, Almeida B, Palman J, Bale P, Heard C, Holzinger D, Roth J, Foell D, Robinson E, Ursu S, Wallace C, Gilmour K, Wedderburn LR, Ralph E. Sumner EJ, et al. Among authors: roth j. Clin Rheumatol. 2022 Sep;41(9):2825-2830. doi: 10.1007/s10067-022-06165-4. Epub 2022 Apr 29. Clin Rheumatol. 2022. PMID: 35486225 Free PMC article.
The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis.
Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit LW, ten Cate R, Hoppenreijs EP, Hansmann S, Moncrieffe H, Ursu S, Wedderburn LR, Roth J, Foell D, Wittkowski H. Holzinger D, et al. Among authors: roth j. Ann Rheum Dis. 2012 Jun;71(6):974-80. doi: 10.1136/annrheumdis-2011-200598. Epub 2012 Jan 20. Ann Rheum Dis. 2012. PMID: 22267331
Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis.
Rothmund F, Gerss J, Ruperto N, Däbritz J, Wittkowski H, Frosch M, Wulffraat NM, Wedderburn LR, Holzinger D, Gohar F, Vastert SJ, Brik R, Deslandre CJ, Melo-Gomes JA, Saad Magalhaes C, Barcellona R, Russo R, Gattorno M, Martini A, Roth J, Foell D; Paediatric Rheumatology International Trials Organisation (PRINTO). Rothmund F, et al. Among authors: roth j. Arthritis Care Res (Hoboken). 2014 Jun;66(6):949-55. doi: 10.1002/acr.22248. Arthritis Care Res (Hoboken). 2014. PMID: 24339418 Free article. Clinical Trial.
HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis.
Ombrello MJ, Remmers EF, Tachmazidou I, Grom A, Foell D, Haas JP, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Mellins ED, Ilowite NT, Russo R, Len C, Hilario MO, Oliveira S, Yeung RS, Rosenberg A, Wedderburn LR, Anton J, Schwarz T, Hinks A, Bilginer Y, Park J, Cobb J, Satorius CL, Han B, Baskin E, Signa S, Duerr RH, Achkar JP, Kamboh MI, Kaufman KM, Kottyan LC, Pinto D, Scherer SW, Alarcón-Riquelme ME, Docampo E, Estivill X, Gül A; British Society of Pediatric and Adolescent Rheumatology (BSPAR) Study Group; Childhood Arthritis Prospective Study (CAPS) Group; Randomized Placebo Phase Study of Rilonacept in sJIA (RAPPORT) Investigators; Sparks-Childhood Arthritis Response to Medication Study (CHARMS) Group; Biologically Based Outcome Predictors in JIA (BBOP) Group; de Bakker PI, Raychaudhuri S, Langefeld CD, Thompson S, Zeggini E, Thomson W, Kastner DL, Woo P; International Childhood Arthritis Genetics (INCHARGE) Consortium. Ombrello MJ, et al. Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15970-5. doi: 10.1073/pnas.1520779112. Epub 2015 Nov 23. Proc Natl Acad Sci U S A. 2015. PMID: 26598658 Free PMC article.
IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis.
Arthur VL, Shuldiner E, Remmers EF, Hinks A, Grom AA, Foell D, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Oliveira S, Yeung RSM, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rösen-Wolff A, Minden K, Szymanski AM; INCHARGE Consortium; Thomson W, Kastner DL, Woo P, Ombrello MJ. Arthur VL, et al. Arthritis Rheumatol. 2018 Aug;70(8):1319-1330. doi: 10.1002/art.40498. Epub 2018 Jun 28. Arthritis Rheumatol. 2018. PMID: 29609200 Free PMC article.
4,904 results